Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-08-21

Study Completion Date

2024-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers. Studying individuals who are positive for a genetic mutation and immediate biological family members (including a parent, full-sibling, or child) may help identify cancer genes and other persons at risk.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

NCT00858078

BRCA1 Gene BRCA2 Gene

COMPLETED

Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

NCT05877404

Endometrial Cancer

TERMINATED

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

NCT04537702

Ovarian Cancer, Epithelial Peritoneal Cancer Fallopian Tube Cancer

COMPLETED NA

Estrogen, Diet, Genetics and Endometrial Cancer

NCT00587886

Cancer Endometrial Cancer Ovarian Cancer +2 more

ACTIVE_NOT_RECRUITING

Registry for Women Who Are At Risk Or May Have Lynch Syndrome

NCT00508573

Hereditary Nonpolyposis Colorectal Cancer Lynch Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Identify and explore factors influencing the communication of genetic testing results from probands (patients with confirmed hereditary cancer predisposition syndrome) to their first-degree relatives. (Step 1) II. Identify and explore factors influencing decision making and pursuit of cascade testing among first-degree relatives of probands. (Step 1) III. Estimate the uptake of cascade testing by first-degree relatives of probands at a safety-net hospital and the uptake of cascade testing by first-degree relatives of probands at a comprehensive cancer center. (Step 2) IV. Estimate the frequency of reported factors that influence communication, decision-making, and pursuit of cascade testing among probands and their first-degree family members at a safety-net hospital and at a comprehensive cancer center. (Step 2) V. Explore similarities and differences in cascade genetic testing rates and reported barriers to cascade genetic testing of first-degree relatives at probands from a safety-net hospital and a comprehensive cancer center. (Step 2)

OUTLINE:

STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.

STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Carcinoma Deleterious CDH1 Gene Mutation Deleterious DICER1 Gene Mutation Deleterious SMARCA4 Gene Mutation Deleterious STK11 Gene Mutation Endometrial Carcinoma Fallopian Tube Carcinoma Ovarian Carcinoma Primary Peritoneal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (interview, survey)

STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes.

STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes.

Interview

Intervention Type OTHER

Participate in semi-structure, in-depth qualitative interviews

Questionnaire Administration

Intervention Type OTHER

Complete questionnaires

Survey Administration

Intervention Type OTHER

Complete survey

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interview

Participate in semi-structure, in-depth qualitative interviews

Intervention Type OTHER

Questionnaire Administration

Complete questionnaires

Intervention Type OTHER

Survey Administration

Complete survey

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* STEP 1 (PROBANDS): Speaks and/or reads English or Spanish
* STEP 1 (PROBANDS): Currently receiving diagnostic, treatment, or follow-up care in the outpatient gynecologic oncology and medical oncology clinics at LBJ
* STEP 1 (PROBANDS): Has completed genetic counseling, with pedigree available in the medical record (LBJ)
* STEP 1 (PROBANDS): Diagnosed with female-breast, ovarian, fallopian tube, primary peritoneal, endometrial cancer on or after January 1, 2014
* STEP 1 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1)
* STEP 1 (FIRST-DEGREE RELATIVE \[FDR\]): Speaks and/or reads English or Spanish
* STEP 1 (FDR): Is a first-degree relative of proband (son, daughter, full-brother, full-sister, mother, father)
* STEP 1 (FDR): Is present with proband at time of recruitment, or can be contacted by telephone via a United States (U.S.) telephone number
* STEP 1 (FDR): Is aware of proband's genetic testing result/mutation status, per proband report
* STEP 2 (PROBANDS): Speaks or reads English or Spanish
* STEP 2 (PROBANDS): Currently receives diagnostic, treatment, or follow-up care for female-breast cancer in the outpatient medical oncology clinics at LBJ; or currently receives diagnostic, treatment, or follow-up care for ovarian, fallopian tube, primary peritoneal or endometrial cancer in the outpatient gynecologic oncology clinic at LBJ or the outpatient gynecologic oncology clinic at The University of Texas MD Anderson Cancer Center (MD Anderson)
* STEP 2 (PROBANDS): Diagnosed with eligible cancer on or after January 1, 2014
* STEP 2 (PROBANDS): Has completed genetic counseling, with a pedigree available in the medical record (LBJ) or internal clinical and research database (progeny at MD Anderson)
* STEP 2 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1)
* STEP 2 (FDR): Speak and/or reads English or Spanish
* STEP 2 (FDR): First-degree relative of proband (son, daughter, full-brother, full-sister, mother, father)
* STEP 2 (FDR): Is present with proband at time of recruitment, or can be contacted by telephone via a U.S. telephone number
* STEP 2 (FDR): Is aware of proband's genetic testing result/mutation status, per proband report

Exclusion Criteria

* STEP 1 (PROBANDS): No longer receives outpatient care at LBJ
* STEP 1 (PROBANDS): Has a negative genetic testing result, a result identifying only a variant of uncertain significance, or results and pedigree that cannot be confirmed in the electronic medical record
* STEP 1 (PROBANDS): Is unwilling or unable to provide informed consent
* STEP 1 (FIRST-DEGREE RELATIVE \[FDR\]): Unwilling or unable to provide informed consent
* STEP 2 (PROBANDS): No longer receives outpatient care at LBJ or MD Anderson
* STEP 2 (PROBANDS): Has a negative genetic testing result, a result identifying only a variant of uncertain significance, or results and pedigree that cannot be confirmed in the electronic medical record
* STEP 2 (PROBANDS): Unwilling or unable to provide informed consent
* STEP 2 (PROBANDS): Participated in step 1 interviews
* STEP 2 (FDR): Unwilling or unable to provide informed consent
* STEP 2 (FDR): Reports no knowledge of proband's genetic testing status
* STEP 2 (FDR): Participated in step 1 interviews

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes